- Home
- NVS vs NVO Comparison
NVS vs NVO Comparison
Compare NVS & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVS
- NVO
- Stock Information
- Founded
- NVS 1895
- NVO 1923
- Country
- NVS Switzerland
- NVO Denmark
- Employees
- NVS N/A
- NVO N/A
- Industry
- NVS Biotechnology: Pharmaceutical Preparations
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVS Health Care
- NVO Health Care
- Exchange
- NVS Nasdaq
- NVO Nasdaq
- Market Cap
- NVS 254.8B
- NVO 243.4B
- IPO Year
- NVS 1991
- NVO N/A
- Fundamental
- Price
- NVS $122.61
- NVO $50.04
- Analyst Decision
- NVS Hold
- NVO Buy
- Analyst Count
- NVS 5
- NVO 10
- Target Price
- NVS $119.00
- NVO $80.40
- AVG Volume (30 Days)
- NVS 1.8M
- NVO 10.6M
- Earning Date
- NVS 10-28-2025
- NVO 11-05-2025
- Dividend Yield
- NVS 2.13%
- NVO 2.40%
- EPS Growth
- NVS N/A
- NVO 24.25
- EPS
- NVS 7.30
- NVO 3.93
- Revenue
- NVS $56,372,000,000.00
- NVO $49,108,936,497.00
- Revenue This Year
- NVS $9.06
- NVO $9.58
- Revenue Next Year
- NVS $2.54
- NVO $7.39
- P/E Ratio
- NVS $16.69
- NVO $13.08
- Revenue Growth
- NVS 12.88
- NVO 20.91
- 52 Week Low
- NVS $96.06
- NVO $45.05
- 52 Week High
- NVS $133.55
- NVO $113.76
- Technical
- Relative Strength Index (RSI)
- NVS 32.08
- NVO 28.27
- Support Level
- NVS $121.57
- NVO $52.38
- Resistance Level
- NVS $132.33
- NVO $53.55
- Average True Range (ATR)
- NVS 1.64
- NVO 0.99
- MACD
- NVS -1.33
- NVO -0.60
- Stochastic Oscillator
- NVS 5.98
- NVO 5.24
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.